Compare Stocks

→ This company has increased its dividend every year for 54 years (From DTI) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLR Allarity Therapeutics	$1.54 +2.7%	$6.54	$1.28 ▼ $628.00	$477K	0.25	399,467 shs	762,292 shs
APLIF Appili Therapeutics	$0.03	$0.02	$0.02 ▼ $0.08	$3.54M	-0.3	449,634 shs	3,030 shs
CPMD CannaPharmaRX	$0.01	$0.01	$0.00 ▼ $0.03	$6.61M	2.12	997,159 shs	50,000 shs
ENDV Endonovo Therapeutics	$0.00	$0.00	$0.00 ▼ $0.02	$799K	-1.41	3.07 million shs	349,914 shs

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLR Allarity Therapeutics	-10.71%	-53.56%	-78.57%	-83.24%	-99.84%
APLIF Appili Therapeutics	+1.04%	-9.32%	+19.18%	+25.86%	+8.15%
CPMD CannaPharmaRX	-22.48%	-29.08%	-16.67%	+614.29%	-4.76%
ENDV Endonovo Therapeutics	-25.00%	-7.69%	+4.35%	-74.74%	-83.45%

AI “wealth window” is closing soon! (Ad)

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLR Allarity Therapeutics	0.151 of 5 stars	0.0	4.0	0.0	0.0	2.3	0.0	0.0
APLIF Appili Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CPMD CannaPharmaRX	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ENDV Endonovo Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLR Allarity Therapeutics	N/A	N/A	N/A	N/A
APLIF Appili Therapeutics	N/A	N/A	N/A	N/A
CPMD CannaPharmaRX	N/A	N/A	N/A	N/A
ENDV Endonovo Therapeutics	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLR Allarity Therapeutics	N/A	N/A	N/A	N/A	($18.63) per share	N/A
APLIF Appili Therapeutics	$280K	12.65	N/A	N/A	($0.05) per share	-0.58
CPMD CannaPharmaRX	N/A	N/A	N/A	N/A	($0.07) per share	N/A
ENDV Endonovo Therapeutics	$140K	5.71	N/A	N/A	($0.15) per share	-0.02

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLR Allarity Therapeutics	-$11.90M	N/A	0.00	N/A	N/A	N/A	N/A	-91.78%	5/9/2024 (Estimated)
APLIF Appili Therapeutics	-$6.99M	-$0.04	N/A	N/A	N/A	-456.86%	N/A	-229.96%	6/21/2024 (Estimated)
CPMD CannaPharmaRX	-$8.53M	-$0.03	N/A	∞	N/A	N/A	N/A	-141.66%	N/A
ENDV Endonovo Therapeutics	-$18.48M	N/A	0.00	∞	N/A	-1,717.21%	N/A	-408.63%	N/A

Latest CPMD, ENDV, APLIF, and ALLR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
2/13/2024	Q3 2024	APLIF Appili Therapeutics	-$0.01	-$0.01	N/A	N/A	N/A	$0.36 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLR Allarity Therapeutics	N/A	N/A	N/A	N/A	N/A
APLIF Appili Therapeutics	N/A	N/A	N/A	N/A	N/A
CPMD CannaPharmaRX	N/A	N/A	N/A	N/A	N/A
ENDV Endonovo Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLR Allarity Therapeutics	N/A	0.14	0.14
APLIF Appili Therapeutics	N/A	0.46	0.46
CPMD CannaPharmaRX	N/A	N/A	N/A
ENDV Endonovo Therapeutics	N/A	N/A	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
ALLR Allarity Therapeutics	11.53%
APLIF Appili Therapeutics	N/A
CPMD CannaPharmaRX	N/A
ENDV Endonovo Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ALLR Allarity Therapeutics	0.08%
APLIF Appili Therapeutics	11.84%
CPMD CannaPharmaRX	1.27%
ENDV Endonovo Therapeutics	5.61%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLR Allarity Therapeutics	5	310,000	309,000	Not Optionable
APLIF Appili Therapeutics	8	121.27 million	106.91 million	Not Optionable
CPMD CannaPharmaRX	6	660.63 million	652.24 million	Not Optionable
ENDV Endonovo Therapeutics	1	333.04 million	314.36 million	Not Optionable

CPMD, ENDV, APLIF, and ALLR Headlines

Source	Headline
	Endonovo Closes Asset Purchase Agreement for a Minimum of $50M With SofPulse, Inc globenewswire.com - March 28 at 9:03 AM
	Endonovo’s SofPulse® to Be Featured at Innovative Pain Management Solutions finance.yahoo.com - March 4 at 1:06 PM
	Endonovo's SofPulse® to Be Featured at Innovative Pain Management Solutions globenewswire.com - March 4 at 9:09 AM
	Endonovo Signs Definitive Agreement to Sell SofPulse® Brand Business and IP to SofPulse Inc. for a minimum of $50 Million finance.yahoo.com - December 4 at 12:48 PM
	Endonovo Therapeutics, Inc. (ENDV) finance.yahoo.com - November 21 at 6:56 PM
	Lexeo Therapeutics Inc (LXEO) investing.com - November 15 at 2:10 PM
	Endonovo receives Taiwanese approval for SofPulse technology msn.com - October 13 at 12:28 PM
	Endonovo's SofPulse® Secures Taiwan FDA Approval finance.yahoo.com - October 12 at 10:51 AM
	Endonovo’s SofPulse® Secures Federal Supply Schedule Inclusion to Accelerate Expansion of VA Distribution finance.yahoo.com - August 22 at 9:24 AM
	Endonovo’s Breaking Barriers in With Patented Medical Technologies: 2023 Bi-Annual Update finance.yahoo.com - August 8 at 12:48 PM
	New to The Street TV Signs 6 Part Series, Featuring Endonovo Therapeutics, Inc. finance.yahoo.com - June 22 at 2:45 PM
	New to The Street TV Signs 6 Part Series, Featuring Endonovo Therapeutics, Inc. finance.yahoo.com - June 22 at 2:45 PM
	Endonovo Pending Agreement to Develop Telehealth Division finance.yahoo.com - June 7 at 10:30 AM
	Endonovo Launches SofPulse® into the Veterans Administration finance.yahoo.com - May 2 at 12:56 PM
	Endonovo Reaches Out to Top Clinical Researchers to Collaborate on TBI Treatment Studies finance.yahoo.com - April 25 at 1:38 PM
	Endonovo Announces Partnership with Former NFL Dallas Cowboy Defensive Lineman finance.yahoo.com - April 13 at 10:55 AM
	Endonovo Announces Partnership with Santana Lead Singer Andy Vargas finance.yahoo.com - April 10 at 4:13 PM
	Endonovo Announces Binding Letter of Intent to Sell SofPulse® Assets to Spin-Off Company finance.yahoo.com - March 29 at 12:50 PM
	Endonovo’s SofPulse® Nears Final Stages to Receive Taiwan FDA License to Distribute in Taiwan finance.yahoo.com - March 23 at 1:01 PM
	Olympian and Champion Surfer Carlos Muñoz Turns To SofPulse® For Accelerated Recovery After Invasive Shoulder Surgery finance.yahoo.com - March 15 at 1:21 PM
	Endonovo Therapeutics (OTCMKTS:ENDV) Reaches Distribution Agreement with Academy Medical finance.yahoo.com - March 9 at 7:42 AM
	Endonovo Announces Distribution Agreement with Academy Medical finance.yahoo.com - March 6 at 10:14 AM
	Endonovo Announces Q&A with Newly-Appointed SofPulse® Medical Division President, Ira Weisberg finance.yahoo.com - February 28 at 10:39 AM
	Endonovo Retains Ocean Tomo, a Part of J.S. Held, to Provide Fairness Opinion Analysis for Medical Device Spin-Off finance.yahoo.com - January 31 at 10:12 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Allarity Therapeutics

NASDAQ:ALLR

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. Allarity Therapeutics, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.

Appili Therapeutics

OTCMKTS:APLIF

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.

CannaPharmaRX

OTCMKTS:CPMD

CannaPharmaRX, Inc. operates in the cannabis industry in Canada. It evaluates, negotiates, acquires, and develops various cannabis cultivation projects. The company was incorporated in 1998 and is based in Calgary, Canada.

Endonovo Therapeutics

OTCMKTS:ENDV

Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardiovascular diseases, chronic kidney, liver diseases, non-alcoholic steatohepatitis, cardiovascular and peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, stroke, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial